COST-EFFECTIVENESS OF BRENTUXIMAB VEDOTIN IN RELAPSED OR REFRACTORY SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA IN TAIWAN

被引：1
|
作者：
Zou, D. [1 ]
Kendall, R. [1 ]
Lin, Q. [2 ]
Huang, Y. [2 ]
Tieng, J. [3 ]
Tseng, J. [3 ]
Sajosi, P. [4 ]
机构：
[1] ICON Plc, Vancouver, BC, Canada
[2] Kantar Hlth, Taipei, Taiwan
[3] Takeda Pharmaceut Taiwan, Taipei, Taiwan
[4] Takeda Pharmaceut Int AG, Zurich, Switzerland
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.08.705
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CE2
引用
收藏
页码：A811 / A811
页数：1
相关论文
共 50 条
  • [31] Remission of refractory granulomatous primary cutaneous anaplastic large cell lymphoma to brentuximab vedotin
    Sasapu, Appalanaidu
    Dunn, Andrew L. J.
    Gardner, Jerad
    Wong, Henry K.
    BMJ CASE REPORTS, 2021, 14 (07)
  • [32] EFFICACY OF BRENTUXIMAB VEDOTIN AND OTHER TREATMENTS IN PATIENTS WITH RELAPSED OR REFRACTORY (RR) SYSTEMIC ANAPLASTIC LARGE-CELL LYMPHOMA (SALCL): A SYSTEMATIC REVIEW
    Hamashima, C.
    Ogoshi, K.
    Okamoto, M.
    Shabana, M.
    Kishimoto, T.
    Fukao, A.
    VALUE IN HEALTH, 2013, 16 (07) : A395 - A395
  • [33] FDA Approves Brentuximab Vedotin for Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma
    不详
    ONCOLOGY-NEW YORK, 2011, 25 (10): : 904 - +
  • [34] REAL LIFE EXPERIENCE WITH BRENTUXIMAB VEDOTIN: THE ITALIAN STUDY ON 40 RELAPSED/REFRACTORY ANAPLASTIC LARGE CELL LYMPHOMA PATIENTS
    Quirini, F.
    Broccoli, A.
    Pellegrini, C.
    Di Rocco, A.
    Puccini, B.
    Patti, C.
    Gini, G.
    Mannina, D.
    Tani, M.
    Rusconi, C.
    Romano, A.
    Vanazzi, A.
    Botto, B.
    Carlo-Stella, C.
    Hoaus, S.
    Musto, P.
    Mazza, P.
    Molica, S.
    Corradini, P.
    Fama, A.
    Gaudio, F.
    Merli, M.
    Gravetti, A.
    Gritti, G.
    Arcari, A.
    Tosi, P.
    Liberati, A. M.
    Pinto, A.
    Pavone, V.
    Gherlinzoni, F.
    Naso, V.
    Volpetti, S.
    Trentin, L.
    Goldaniga, M. C.
    Bonfichi, M.
    De Renzo, A.
    Schiavotto, C.
    Spina, M.
    Storti, S.
    Carella, A. M.
    Stefoni, V.
    Argnani, L.
    Zinzani, P. L.
    HAEMATOLOGICA, 2017, 102 : 50 - 51
  • [35] Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma
    Vaklavas, Christos
    Forero-Torres, Andres
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2012, 3 (04) : 209 - 225
  • [36] Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma
    Song, Yuqin
    Guo, Ye
    Huang, Huiqiang
    Li, Wei
    Ke, Xiaoyan
    Feng, Jifeng
    Xu, Wei
    Miao, Harry
    Kinley, Judith
    Song, Gregory
    Dai, Yi
    Wang, Hui
    Zhu, Jun
    EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (09) : 867 - 875
  • [37] Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study
    Izutsu, Koji
    Ogura, Michinori
    Tobinai, Kensei
    Hatake, Kiyohiko
    Sakamoto, Shigeru
    Nishimura, Masanori
    Hoshino, Miyako
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (03) : 404 - 412
  • [38] Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin
    Chen, Xueyan
    Soma, Lorinda A.
    Fromm, Jonathan R.
    ONCOTARGETS AND THERAPY, 2014, 7 : 45 - 56
  • [39] Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study
    Koji Izutsu
    Michinori Ogura
    Kensei Tobinai
    Kiyohiko Hatake
    Shigeru Sakamoto
    Masanori Nishimura
    Miyako Hoshino
    International Journal of Hematology, 2021, 113 : 404 - 412
  • [40] THE COST-EFFECTIVENESS OF NIVOLUMAB FOR THE TREATMENT OF PEOPLE WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANT AND BRENTUXIMAB VEDOTIN
    Jones, B.
    Ward, T.
    Harrison, J. P.
    Hurst, M.
    Tyas, D.
    McEwan, P.
    Gordon, J.
    VALUE IN HEALTH, 2017, 20 (09) : A433 - A433
12345